Vanda Pharmaceuticals (VNDA) Cash from Investing Activities (2010 - 2026)

Vanda Pharmaceuticals (VNDA) has 17 years of Cash from Investing Activities data on file, last reported at $20.2 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Investing Activities fell 53.91% year-over-year to $20.2 million; the trailing twelve-month figure through Mar 2026 stood at $71.2 million (up 59.3% YoY), and the FY2025 full-year result was $94.9 million, up 644.23% from the prior year.
• Cash from Investing Activities fell to $20.2 million in Q1 2026, from $44.9 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $187.3 million in Q1 2023 to a low of -$190.9 million in Q2 2023.
• A 5-year average of $8.0 million and a median of $10.9 million in 2022 frame the typical range for Cash from Investing Activities.
• Across the five-year window, Cash from Investing Activities surged 15204.23% in 2022 and sank 1208.21% in 2023, its largest moves.
• Tracing VNDA's Cash from Investing Activities over 5 years: stood at $75.4 million in 2022, then tumbled by 158.05% to -$43.8 million in 2023, then surged by 109.12% to $4.0 million in 2024, then soared by 1023.62% to $44.9 million in 2025, then tumbled by 54.9% to $20.2 million in 2026.
• Business Quant data shows VNDA's Cash from Investing Activities at $20.2 million in Q1 2026, $44.9 million in Q4 2025, and $21.4 million in Q3 2025.